UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549


FORM 10-Q


(Mark One)
þQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2013

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012
Or
¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to ____________

Commission File Number: 2-93277-D

MEDIZONE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
 
Nevada87-0412648
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

4000 Bridgeway, Suite 401, Sausalito, California  94965
(Address of principal executive offices, Zip Code)

(415) 331-0303
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ No¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨
Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)
Smaller reporting companyReporting Company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ¨ No þ

At October 25, 2012,As of April 26, 2013, the registrant had 286,536,927301,004,559 shares of common stock issued and outstanding.

 
 
 
MEDIZONE INTERNATIONAL, INC.
FORM 10-Q

TABLE OF CONTENTS
September 30, 2012March 31, 2013
 
  Page No.
Part I — Financial Information 
   
Item 1.
Financial Statements
3
   
 
Consolidated Balance Sheets: September 30, 2012March 31, 2013 (Unaudited) and December 31, 20112012 (Audited)
3
   
 
Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited): For the Three and Nine Months Ended September 30,March 31, 2013 and 2012 and 2011
4
   
 
Consolidated Statements of Cash FlowFlows (Unaudited): For the NineThree Months Ended September  30,March 31, 2013 and 2012 and 2011
5
   
 
Notes to the Consolidated Financial Statements (Unaudited)
67
   
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
1413
   
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
2115
   
Item 4.
Controls and Procedures
2115
   
Part II — Other Information 
   
Item 1.
Legal Proceedings
2216
   
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
2216
Item 5.
Other Information
16
   
Item 6.
Exhibits
2216
   
Signatures
2317

 
 
 
PART I —– FINANCIAL INFORMATION
Item 1.  Financial Statements

MEDIZONE INTERNATIONAL,, INC. AND SUBSIDIARIES
Consolidated Balance Sheets

(unaudited)
September 30, December 31, 
2012 2011 March 31, December 31, 
(Unaudited) (Audited) 2013 2012 (1) 
ASSETS    ASSETS 
        
CURRENT ASSETS    
Current Assets    
Cash $244,120 $129,759  $49,933  $12,456 
Inventory
  45,548   45,548 
Prepaid expenses 73,240 47,286   161,173   118,344 
Inventory  91,547  - 
Total Current Assets  408,907  177,045   256,654   176,348 
     
PROPERTY AND EQUIPMENT (NET)  5,418  3,975 
     
OTHER ASSETS     
Property and equipment, net
  5,307   5,964 
Other Assets
        
Trademark and patents, net 210,749 146,342   205,128   208,490 
     
Lease deposit  4,272  4,272   4,272   4,272 
Total Other Assets  215,021  150,614   209,400   212,762 
Total Assets
 $471,361  $395,074 
             
TOTAL ASSETS $629,346 $331,634 
LIABILITIES AND STOCKHOLDERS' DEFICIT
LIABILITIES AND STOCKHOLDERS' DEFICIT
 
             
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)     
     
CURRENT LIABILITIES     
Current Liabilities
        
Accounts payable $505,903 $475,912  $499,322  $453,885 
Accounts payable – related parties 259,609 229,669   234,608   234,572 
Accrued expenses 477,227 451,986   493,603   487,690 
Accrued expenses – related parties 1,961,897 1,960,527   1,975,672   1,975,084 
Customer deposits  50,000 40,000   30,000   34,554 
Notes payable  311,477  283,249   307,064   298,536 
Total Current Liabilities  3,566,113  3,441,343   3,540,269   3,484,321 
CONTINGENT LIABILITIES  224,852  224,852 
Other payables
  224,852   224,852 
Commitments and Contingencies (Note 4 and 5)
        
Total Liabilities
  3,765,121   3,709,173 
             
TOTAL LIABILITIES  3,790,965  3,666,195 
     
STOCKHOLDERS' EQUITY (DEFICIT)     
     
Stockholders’ Deficit
        
Preferred stock, 50,000,000 shares authorized of $0.00001 par value, no shares issued or outstanding - -   -   - 
Common stock, 395,000,000 shares authorized of $0.001 par value, 286,536,927 and 272,041,949 shares issued and outstanding, respectively 286,537 272,042 
Common stock, 395,000,000 shares authorized of $0.001
par value, 301,004,559 and 288,771,227 shares issued
and outstanding, respectively
  301,005   288,771 
Additional paid-in capital 26,357,543 23,155,777   26,902,141   26,506,566 
Other comprehensive loss  (22,671)  (21,082)
Accumulated other comprehensive loss
  (24,616)  (24,444)
Accumulated deficit  (29,783,028)   (26,741,298)  (30,472,290)  (30,084,992)
Total Stockholders' Deficit  (3,161,619)   (3,334,561)  (3,293,760)  (3,314,099)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $629,346 $331,634 
Total Liabilities and Stockholders’ Deficit
 $471,361  $395,074 
 
The accompanying notes are an integral part of these consolidated financial statements.

(1)  The consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance as of that date.   
 
 
3

MEDIZONE INTERNATIONAL,, INC., AND SUBSIDIARIES
Consolidated Statements of Operations and Other Comprehensive Loss
(Unaudited)

  For the  For the 
  Three Months Ended  Nine Months Ended 
  September 30,  September 30, 
  2012  2011  2012  2011 
REVENUES $150,000  $-  $150,000  $- 
                 
EXPENSES                
Cost of sales  86,725   -   86,725   - 
General and administrative  932,872   283,730   2,514,018   712,831 
Research and development  187,126   189,688   546,054   778,982 
Expense on extension of warrants  -   -   -   - 
Depreciation and amortization  9,561   5,390   26,488   15,796 
Bad debt expense  -   -   -   - 
     Total Expenses  1,216,284   478,808   3,173,285   1,507,609 
        Loss from Operations  (1,066,284)   (478,808)  (3,023,285)   (1,507,609)
                 
OTHER INCOME (EXPENSES)                
Gain on sale of subsidiaries  -   -   -   - 
Debt forgiveness  -   -   -   - 
Non-controlling interest in loss  -   -   -   - 
Other income  -   -   -   - 
Interest expense  (6,097)   (6,232)  (18,445)   (18,910)
Loss on termination of license agreement  -   -   -   - 
     Total Other Expenses  (6,097)   (6,232)  (18,445)   (18,910)
                 
LOSS BEFORE EXTRAORDINARY ITEMS  (1,072,381)   (485,040)  (3,041,730)   (1,526,519)
                 
EXTRAORDINARY ITEMS                
Debt forgiveness  -   -   -   - 
Lawsuit settlement  -   -   -     
     Total Extraordinary Items  -   -   -   - 
                 
NET LOSS $(1,072,381)  $(485,040) $(3,041,730)  $(1,526,519)
                 
OTHER COMPREHENSIVE LOSS                
(Loss) gain on foreign currency translation  957   (10,466)  (1,589)   (15,427)
                 
TOTAL COMPREHENSIVE LOSS  (1,071,424)   (495,506)  (3,043,319)   (1,541,946)
                 
BASIC LOSS PER SHARE $(0.00) $(0.00) $(0.01) $(0.01)
                 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING  282,697,797   269,632,672   280,103,399   264,562,692 
  For the Three Months Ended 
  March 31, 
  2013  2012 
Revenues
 
$
4,554
  
$
-
 
Operating Expenses
        
Cost of revenues
  
4,000
   
-
 
General and administrative
  
285,211
   
1,329,766
 
Research and development
  
85,771
   
68,249
 
Depreciation and amortization
  
10,504
   
7,861
 
Total Operating Expenses
  
385,486
   
1,405,876
 
Loss from Operations
  
(380,932
)
  
(1,405,876
)
Interest expense
  
(6,366
)
  
(6,185
)
Net Loss
  
(387,298
)
  
(1,412,061
)
Other Comprehensive Loss: Loss on foreign currency translation
  
(172
)
  
(908
)
Total Comprehensive Loss
 
$
(387,470
)
 
$
(1,412,969
)
Basic and Diluted Net Loss per Common Share
 
$
(0.00
)
 
$
(0.00
)
         
Weighted Average Number of Common Shares Outstanding
  
295,469,004
   
277,646,110
 
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
4
 
MEDIZONE INTERNATIONAL,, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(Unaudited)
 
  For the Nine Months Ended 
  September 30, 
  2012  2011 
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $(3,041,730)  $(1,526,519)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization  26,416   15,735 
Amortization of deferred consulting fees  -   59,423 
Value of stock options granted  1,931,325   22,886 
Changes in assets and liabilities:        
Inventories  (91,547)   - 
Prepaid expenses and lease deposit  28,724   (62,997)
Accounts payable and accounts payable-related parties  59,931   46,963 
Accrued expenses and accrued expenses-related parties  26,611   16,425 
Customer deposits  10,000   40,000 
Net Cash Used in Operating Activities  (1,050,270)   (1,388,084)
CASH FLOWS FROM INVESTING ACTIVITIES:        
Trademark and patent costs  (89,118)   (48,377)
Purchase of property and equipment  (3,148)    (4,404) 
Net Cash Used in Investing Activities  (92,266)   (52,781)
CASH FLOWS FROM FINANCING ACTIVITIES:        
Principal payments on notes payable  (26,449)   (2,775)
Payment on stockholder advances  -   (6,000)
Stock issuance costs  -   (4,300)
Issuance of common stock and subscribed for cash  1,284,935   1,390,905 
Net Cash Provided by Financing Activities  1,258,486   1,377,830 
EFFECT ON CURRENCY EXCHANGE RATE CHANGES ON CASH  (1,589)  (15,427)
NET INCREASE (DECREASE) IN CASH  114,361   (78,462)
CASH AT BEGINNING OF PERIOD  129,759   435,894 
CASH AT END OF PERIOD $244,120  $357,432 
         
         
         
SUPPLEMENTAL CASH FLOW INFORMATION        
CASH PAID FOR:        
Interest $702  $1,212 
NON-CASH FINANCING ACTIVITIES        
Financing of insurance policy $54,678  $6,939 
  For the Three Months Ended 
  March 31, 
  2013  2012 
Cash Flows from Operating Activities:      
Net loss
 
$
     (387,298
)
 
$
(1,412,061
)
Adjustments to reconcile net loss to net cash
 Used in operating activities:
        
Depreciation and amortization
  
10,483
   
7,840
 
Stock-based compensation
  
40,809
   
1,057,600
 
Changes in operating assets and liabilities:
        
Prepaid expenses
  
(15,579
)
  
(115,444
)
Customer deposits
  
(4,554)
   
-
 
Accounts payable and accounts payable – related parties
  
45,473
   
(66,882
)
Accrued expenses and accrued expenses – related parties
  
6,501
   
(16,673
)
Net Cash Used in Operating Activities
  
(304,165
)
  
(545,620
)
Cash Flows from Investing Activities:
        
Purchase of trademark and patents
  
(6,464
)
  
(53,119
)
Purchase of property and equipment
  
-
   
(3,149
)
Net Cash Used in Investing Activities
  
(6,464
)
  
(56,268
)
Cash Flows from Financing Activities:
        
Principal payments on notes payable
  
(18,722
)
  
(5,727
)
Issuance of common stock for cash
  
367,000
   
814,310
 
Net Cash Provided by Financing Activities
  
348,278
   
808,583
 
Effect of Foreign Currency Exchange Rates
  
(172
)
  
(908
)
Net increase in cash
  
37,477
   
205,787
 
Cash as of beginning of the period
  
12,456
   
129,759
 
Cash as of end of the period
 
$
49,933
  
$
335,546
 
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
5
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows (Continued)
(Unaudited)
  For the Three Months Ended 
  March 31, 
  2013  2012 
       
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash Paid For:
      
Interest
 
$
307
  
$
181
 
NON-CASH FINANCING ACTIVITIES:
        
Financing of insurance policies
 
$
27,250
  
$
18,635
 

The accompanying notes are an integral part of these consolidated financial statements.
6
MEDIZONE INTERNATIONAL,, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2012March 31, 2013 and December 31, 20112012

NOTE 1     BASIS OF PRESENTATION

The financial information included herein is unaudited and has been prepared consistent with accounting principlesUS generally accepted in the United States of Americaaccounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all information and footnotesnotes required by US GAAP for complete consolidated financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2011.2012. In the opinion of management, these consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of results for the interim period presented. The results of operations for the three- and nine-month periodsthree months ended September 30, 2012March 31, 2013 are not necessarily indicative of the results to be expected for the full year.

Development Stage Company
Historically, the Company has been considered a Development Stage Company. As a result of operations and revenues during 2012, the Company has fully commenced its planned operations, generated significant revenues, and is no longer considered a Development Stage Company.
NOTE 2  SIGNIFICANT ACCOUNTING POLICIES
Inventory
The Company’s inventory consists of its AsepticSure product and is valued on a “first-in first-out” basis at the lower of average cost or market. The Company purchases its inventory as a finished product from unrelated manufacturing companies. The Company writes off 100% of the cost of inventory that it specifically identifies and considers obsolete or excessive to fulfill future sales estimates. The Company did not deem any inventory obsolete or excessive as of September 30, 2012.
Revenue Recognition
The Company recognizes revenue when it ships its products, reasonably expects to receive payment from its customers and training has been completed. The Company records customer deposits that have not yet been earned as unearned revenue. Revenue is recognized only when title and risk of loss passes to customers.
NOTE 32     CANADIAN FOUNDATION FOR GLOBAL HEALTH

In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible.

Accounting standards require a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity ismay be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate it. The Company determined that CFGH meets the requirements of a VIE effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial condition and operations of CFGH are beinghave been consolidated with the Company for the three and nine-monthall periods ended September 30, 2012, September 30, 2011, and December 31, 2011.
6
presented.

MEDIZONE INTERNATIONAL, INC.NOTE 3     BASIC AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2012 and December 31, 2011
NOTE 4  BASICDILUTED NET LOSS PER COMMON SHARE

The computations of basic and diluted net loss per share of common stockshare are based on the weighted average number of common shares outstanding during the periods of the consolidated financial statements as follows:
 
  
For the Three Months Ended
September 30,
 
  2012  2011 
Numerator      
- Loss before extraordinary items $(1,072,381) $(485,040)
- Extraordinary items  -   - 
Denominator (weighted average number of common shares outstanding)  282,697,797   269,632,672 
Basic loss per share        
- Before extraordinary items $(0.00) $(0.00)
- Extraordinary items $(0.00) $(0.00)
Basic Loss Per Share $(0.00) $(0.00)

  
For the Nine Months Ended
September 30,
 
  2012  2011 
Numerator      
- Loss before extraordinary items $(3,041,730) $(1,526,519)
- Extraordinary items  -   - 
Denominator (weighted average number of common shares outstanding)  280,103,399   264,562,692 
Basic loss per share        
- Before extraordinary items $(0.01) $(0.01)
- Extraordinary items $(0.00) $(0.00)
Basic Loss Per Share $(0.01) $(0.01)
  For the Three Months Ended March 31, 
  2013  2012 
       
Numerator: Net loss
 
$
(387,298
)
 
$
(1,412,061
)
Denominator: Weighted average number of common shares outstanding
  
295,469,004
   
277,646,110
 
Basic and diluted net loss per common share
 
$
(0.00
)
 
$
(0.00
)
 
Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the periods presented.
 
7
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
March 31, 2013 and December 31, 2012

NOTE 54     GOING CONCERN

The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has incurred significant losses from its inception through September 30, 2012,March 31, 2013, which have resulted in an accumulated deficit of $29,783,028 at September 30, 2012.$30,472,290 as of March 31, 2013.  The Company hasdoes not have funds sufficient to cover its operating costs for the next few12 months, has a working capital deficit of approximately $3,157,206,$3,283,615, and has relied exclusively on debt and equity financing.  Accordingly, there is substantial doubt about its ability to continue as a going concern.

Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and sales, and ultimately, upon the Company’s attaining profitable operations.  The Company will require a substantial, amount of additional funds to complete the development of its products, perform hospital beta testing and to fund additional losses, until future revenues are sufficient to cover the Company’s operating expenses. If the Company wereis unsuccessful in any of theobtaining additional funding, noted below, it will most likelymay be forced to substantially reduce or cease operations.
7

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2012 and December 31, 2011
NOTE 5 GOING CONCERN (Continued)
As discussed in Note 7 below, the Company entered into a Stock Purchase Agreement and established an Equity Line with Mammoth Corporation (“Mammoth”).  The Company does not anticipate needing to draw the full amount of the Equity Line to implement our business plan and to develop and market its location disinfection technologies.  The Company believes that it will need approximately$2,000,000 forapproximately $2,000,000 over the next 12 months for continuedcontinuing research development,expenses, marketing, and related activities, as well as for general corporate purposes, including continued product development.  Pursuant to the Stock Purchase Agreement with Mammoth, the frequencyexpanded manufacturing and amounts of draws are within its control.  The Company is not obligated to make any draws, and the Company may draw any amount up to the full amount of the Equity Line, in its discretion.  The Company does not plan to draw more funds (and correspondingly put more shares to Mammoth) under the Equity Line than is necessary to implement its business plan.sales.  

During 2011,2012, the Company raised a total of $1,545,906$1,420,793 through the sale of 12,679,77816,729,278 shares of common stock at prices ranging from $0.08$0.05 to $0.192$0.165 per share, which funds have been used to keep the Company current in its reporting obligations under the Exchange Act and to pay certain other corporate obligations including the initial costs of development for its hospital disinfection system.  During the ninethree months ended September 30, 2012,March 31, 2013, the Company raised a total of $1,284,935$367,000 through the sale of 14,494,97812,233,332 shares of common stock at prices ranging from $0.05 to $0.165a price of $0.03 per share.  In addition, if the Company were to need additional resources outside the Equity Line, theThe Company believes the Company wouldit will be able to raise additional funds from some of the same investors who have purchased shares from 2009 to 2012,2013, although there is no guarantee that these investors will purchase additional shares.  However, certain of these investors have verbally committed to continue to fund the Company’s projects on a monthly basis, as needed as apparent to subsequent investments.  basis.

The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations.  The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of these uncertainties.
 
8
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
March 31, 2013 and December 31, 2012

NOTE 65     COMMITMENTS AND CONTINGENCIES

The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position or results of operations, or cash flows.operations.

Litigation
Rakas vs. Medizone International, Inc.Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement.  In September 2001, the parties agreed to settle the matter for $25,000.  The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002.  On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties.  The Company has been unable to post the required bond amount as of the date of this report.  Therefore, the Company has recorded, as part of accounts payable, the original default judgment in the amount of $143,000, plus fees totaling $21,308, as of September 30, 2012March 31, 2013 and December 31, 2011.2012.  The Company intends to contest the judgment if and when it is able to in the future.

Contingent Liabilities
Other Payables
As of September 30, 2012March 31, 2013 and December 31, 2011,2012, the Company has recorded contingent liabilitiesother payables totaling $224,852 related to certain past due payables for which the Company has not received invoices or demands for over ten10 years.  Although management of the Company does not believe that the amounts will ever be paid, the amounts are being recorded as contingent liabilitiesother payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired.
The Company’s Board of Directors has approved the following salaries/consulting fees for its key officers: (1) $170,000 a year for the Company’s CEO, which increased to $195,500 effective March 1, 2012, (2) CD$240,000 per year for the Company’s President, and (3) $60,000 a year for the Company’s CFO.
8
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2012 and December 31, 2011
NOTE 6  COMMITMENTS AND CONTINGENCIES (Continued)

Operating Leases
Effective January 1, 2012, our principal executive offices are located in leased premises at 4000 Bridgeway, Suite 401, Sausalito, California.  The lease has a term of one year, through December 31, 2012 with monthly lease payments of $2,100.  Also, we leaseCompany operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which has providedprovides a primary research and development platform as we proceed toward commercialization of our various products.platform.  The lease term was extended toexpired on June 30, 2012, and is now operated on a month-to-month basis with a monthly lease paymentspayment of $1,350 Canadian Dollarsdollars (“CD”) $1,350 plus the applicable Goodsgoods and Services Taxservices tax (“GST”); after June 30, 2012, the. A lease is onfor a month-to-month term.  A second laboratory space for full scale room testing was extended toalso expired on June 30, 2012, and is now operated on a month-to-month basis with a monthly lease payment of $1,250 CD, plus the applicable GST.  
In March 2011, the Company entered into a lease agreement and established its corporate offices in California that includes a monthly lease payment of $2,500 and was renewable on a month-to-month basis following the initial lease term that ended in May 2011.  The Company elected to terminate this lease in December 2011 and enter into a new corporate office lease effective January 1, 2012 through December 31, 2012 with monthly payments of $2,100.  The lease term was extended for another year, through December 31, 2013, with monthly lease payments of CD $1,250, plus the applicable GST; after June 30, 2012, the lease is on a month-to-month term.increasing from $2,100 to $2,200.  
We estimate that our current facilities are sufficient to meet our needs until we begin to have significantly more revenues from operations.

NOTE 76     COMMON STOCK WARRANTS AND OPTIONS

Warrants
All outstanding warrants were either exercised or expired unexercised prior to December 31, 2009, thus there are no warrants outstanding as of September 30, 2012 or December 31, 2011.
Options
InOn August 26, 2009, the Company granted options tofor the purchase a total of 1,500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share, exercisable for up to five years. The options vestedyears, but including vesting provisions as follows: (i) 500,000 of the options vested immediately on the date of grant, (ii) 500,000 options will vestvested on the date certified by the Company as the date the Company’s hospital disinfection program completes its beta-testing, and (iii) the remaining 500,000 options will vest on the date certified by the Company as the date that the Company’s process has been commercialized and a minimum of 50 units or devices have been sold to third parties by the Company.  During the three months ended September 30, 2012, 500,000 options vested totaling $48,699 which was recorded as part of general and administrative expenses.  As of September 30, 2012,March 31, 2013, 500,000 of the 1,500,000 options granted to this consultant had not yet vested.
In July 2010, the Company granted options to purchase a total of 3,500,000 shares to certain board members and employees of the Company as additional compensation for work performed. As of December 31, 2011, options for 250,000 shares were cancelled under this agreement. These options are exercisable for five years at $0.20 per share, but did not vest until the Company has achieved commercial sales. During the three months ended September 30, 2012, these 3,250,000 options vested totaling $659,822 which was recorded as part of general and administrative expenses as the Company achieved commercial sales.
In September 2010, the Company granted options to purchase 250,000 shares to an outside consultant in connection with extending his consulting agreement with the Company through September 2011. These options are exercisable for five years at $0.275 per share, but do not vest until the Company has achieved commercialization and sales of the AsepticSure™ product. During the three months ended September 30, 2012, these 250,000 options totaling $65,067, which was recorded as part of general administrative expenses, as the Company achieved commercial sales.
In March 2011, the Company granted options for the purchase of 150,000 shares of common stock to an individual for accounting related services to be performed through December 30, 2011, which did not vest until such date.  The options have an exercise price of $0.14 per share, and are exercisable for up to five years.  The grant date fair value of these options was $20,042, in connection with which the Company recognized $6,380 and $13,731 of expense during the three and nine months ended September 30, 2011, respectively.  The remaining $6,311 was recognized between October 1, and December 30, 2011.
In March 2011, the Company granted options for the purchase of 100,000 shares of common stock to an individual for web and press support services to be performed through December 30, 2011, which did not vest until such date. The options have an exercise price of $0.14 per share, and are exercisable for up to five years.  The grant date fair value of these options was $13,361, in connection with which the Company recognized $4,254 and $9,155 of expense during the three and nine months ended September 30, 2011, respectively.  The remaining $4,206 was recognized between October 1, and December 30, 2011.
 
 
9
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2012March 31, 2013 and December 31, 20112012

NOTE 76     COMMON STOCK WARRANTS AND OPTIONS (Continued)(continued)

In July 2010, the Company granted options for the purchase of 3,500,000 shares of common stock (of which 250,000 were cancelled in 2011) of common stock to certain board members and employees of the Company for services rendered.  These options are exercisable for five years from the date of grant at $0.20 per share, and vested when the Company achieved commercial sales during the third quarter of 2012.  

In September 2010, the Company granted options for the purchase of 250,000 shares of common stock to a consultant in connection with extending his consulting agreement with the Company through September 2011.  These options are exercisable at $0.275 per share for five years from the date of grant and vested when the Company achieved commercialization and sales of the AsepticSure™ product during the third quarter of 2012.  
 
In February 2012, the Board of Directors approved the 2012 Equity Incentive Award Plan and authorized up to 10,000,000 shares of common stock to be available for awards under the Plan.  On February 21, 2012, each of four directors of the Company was awarded stock options for the purchase of 1,000,000 shares of common stock, exercisable at a price of $0.23 per share, which was the closingfair value of the common stock based on the price of the Company’s common stock reported on the OTC Bulletin Board on the date of grant.  In addition, certain officers, consultants and employees of the Company were awarded options in the aggregate for the purchase of an aggregate 1,050,000 shares of common stock at an exercise price of $0.23 per share.  The value of these options granted, totaling $1,057,600, was recordedrecognized as expense during the ninethree months ended September 30,March 31, 2012 as each of the options granted was fully vested on the date of grant.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for distribution channel related services to be performed, which do notservices.  Options for 200,000 shares have vested and the remaining options will vest until completion of specific milestones.on the date certified by the Company as the date that the other milestones are achieved.  The options have an exercise price of $0.17 per share, and are exercisable for up to five years.  The grant date fair value of these options granted was $153,997 in connection with which the Company recorded no expenserecognized $15,399 during the ninethree months ended September 30, 2012.  The Company will recognize the expense in the future upon achievement of these milestones.March 31, 2013.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for medical consulting support services already performed (vested immediately on the grant date) and to be performed in the future, which do not vest until completion of certain milestones.  The options have an exercise price of $0.17 per share, and are exercisable for up to five years.  The grant date fair value of thesethe vested options granted was $149,460 in connection with which the Company recorded $100,138 of expenserecognized $25,408 during the ninethree months ended September 30, 2012.  The remaining $49,322 will be recorded byMarch 31, 2013.  As of March 31, 2013, options for the Company in the future upon achievementpurchase of 840,000 of the remaining milestones.
1,000,000 shares have vested.
 
In August 2012, the Company granted options for the purchase of 2,500,000 shares of common stock to three individuals in connection with the purchase of restricted stock, exercisable at a price of $0.05 per share.  No expense was recorded for these options as anythe value associated with these options was recorded as part of the stock transactions.
 
The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions:
 
Risk-free interest rate2.46%
Expected life5 years
Expected volatility185.59% to 196.94%
Dividend yield0.00%
Risk-free interest rate     2.46%
Expected life     5 years 
Expected volatility  185.59%to 196.94%
Dividend yield      0.00%

10
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
March 31, 2013 and December 31, 2012

NOTE 6     COMMON STOCK OPTIONS (continued)

A summary of the status of the Company’s outstanding options as of September 30, 2012,March 31, 2013, and changes duringfor the nine-monththree-month period then ended, is presented below:

 Shares Weighted Average Exercise Price  Shares  Weighted Average Exercise Price 
Outstanding, beginning of period 7,750,000 $0.17 
Outstanding, beginning of the period
 
17,300,000
 $
0.17
 
Granted 9,550,000 $0.17  
-
 
-
 
Expired/Canceled - -  
-
 
-
 
Exercised  -  -   
-
  
-
 
Outstanding, end of period  17,300,000 $0.19 
Outstanding, end of the period
  
17,300,000
  
 0.17
 
Exercisable 15,470,000 $0.17  
15,840,000
 
0.17
 

The Company estimates the fair value of each stock award by using the Black-Scholes option pricingoption-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Under the provisionsExpense of this accounting standard, additional expense of $1,931,325$40,809 and $22,886$1,057,600 related to sock options was recorded for the nine-month periodthree-month periods ended September 30,March 31, 2013 and 2012, and 2011, respectively, usingrespectively.  As of March 31, 2013, the Black-Scholes option pricing model.Company had various unvested outstanding options with related unrecognized expense of $196,000.  The Company will recognize this expense as these options vest over their remaining useful lives, which range from 17 to 49 months.

10
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2012 and December 31, 2011
NOTE 87     STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS

During the three months ended March 31, 2013, the Company sold an aggregate of 12,233,332 restricted shares of common stock to 12 accredited investors for cash proceeds totaling $367,000, or $0.03 per share.

During January and February 2012, the Company sold an aggregate of 6,653,000 restricted shares of common stock to approximately 30 accredited investors for cash proceeds of $665,300, at a price ofor $0.10 per share.

During January 2012, the Company issued 903,089 shares of common stock to Mammoth Corporation (“Mammoth”) as part of the a stock equity line (“Equity LineLine”) for cash proceeds of $149,010, at a price ofor $0.165 per share.
During June 2012, the Company issued 500,000 shares of common stock to Mammoth as part of the Equity Line for cash proceeds of $65,625, at a price of $0.131 per share.
During June 2012, the Company sold an aggregate of 1,205,556 restricted shares of common stock to two accredited investors for cash proceeds of $108,500 at a price of $.09 per share.
During July 2012, the Company sold an aggregate of 250,000 restricted shares of common stock to an accredited investor for cash proceeds of $22,500 at a price of $0.09 per share.
During August 2012, the Company sold an aggregate of 2,500,000 restricted shares of common stock to three accredited investors for cash proceeds of $125,000 at a price of $0.05 per share.
During September 2012, the Company sold an aggregate of 2,483,333 restricted shares of common stock to seven accredited investors for cash proceeds of $149,000 at a price of $0.06 per share.

Stock Purchase Agreement
In November 2010, the Company entered into thea two-year Stock Purchase Agreement with Mammoth providing for the Equity Line. The Stock Purchase Agreement provides that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth is committed to purchase up to $10,000,000 of shares of our common stock over the 24-month term of the Stock Purchase Agreement under certain specified conditions and limitations.
Furthermore, in no event may Mammoth purchase any shares of the Company’s common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9 percent4.9% of the then outstanding shares of the Company’s common stock. These maximum share and beneficial ownership limitations may not be waived by the parties.
 
Under the terms of the Stock Purchase Agreement, the Company hashad the opportunity for a 24-month period, commencing on the date on which the SECSecurities and Exchange Commission (“SEC”) first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock. For each share of common stock purchased under the Stock Purchase Agreement, Mammoth will pay to the Company a purchase price equal to 75 percent75% of the lowest closing bid price during the five consecutive trading daytrading-day period (the “Draw Down Pricing Period”) preceding the date a draw down notice (the “Draw Down Notice”) is delivered by the Company to Mammoth (the “Draw Down Date”) in a manner provided by the Stock Purchase Agreement. Subject to the limitations outlined below, the Company may, at its sole discretion, issue a Draw Down Notice to Mammoth, and Mammoth will then be irrevocably bound to purchase such shares.
Each Draw Down Notice must specify  The SEC declared the lowest purchase price during the Draw Down Pricing Period at which the Company will sell the shares to Mammoth, which shall not be less than 75 percent of the lowest closing bid price during the Draw Down Pricing Period.  Furthermore, the number of shares to be issued is limited by multiplying by five the average daily trading volume for the 30  trading days immediately preceding the delivery of the Draw Down Notice.registration statement effective on January 25, 2011.  The Draw Down Notice will also include the aggregate dollar amount of the Draw Down, which will not be less than $25,000Stock Purchase Agreement and not more than $500,000 in any Draw Down Notice. There must be a minimum of 15 trading days between each Draw Down Notice.Equity Line terminated on January 25, 2013.
 
 
11

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2012March 31, 2013 and December 31, 2011
NOTE 8  STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Continued)
The Company agreed to pay up to $5,000 (of which the Company paid $4,300 during the three months ended March 31, 2011 to fully satisfy this obligation) of reasonable attorneys’ fees and expenses (exclusive of disbursements and out-of-pocket expenses) incurred by Mammoth in connection with the preparation, negotiation, execution and delivery of the Stock Purchase Agreement and related transaction documentation. Further, if the Company issues a Draw Down Notice and fails to deliver the shares to Mammoth on the applicable settlement date, and such failure continues for 10 trading days, the Company agreed to pay Mammoth, in addition to all other remedies available to Mammoth under the Stock Purchase Agreement, an amount in cash equal to $100 for each $5,000 of the Draw Down Amount for the first 10 days such delivery is late, and $350 for each $5,000 of the Draw Down Amount for each trading day beyond 10 trading days that such delivery is late.
In connection with the Stock Purchase Agreement, the Company granted registration rights to Mammoth, and agreed to register the resale of shares issued to Mammoth in connection with Draw Downs made in connection with the Stock Purchase Agreement. In January 2011, the Company filed a registration statement to cover the resale by Mammoth of up to 66,666,667 shares of our common stock under the Stock Purchase Agreement. The Company is not permitted to make Draw Downs under the Stock Purchase Agreement at any time there is not an effective registration statement registering the resale of shares of common stock by Mammoth. On January 25, 2011, the registration statement was declared effective by the SEC. The Company has agreed to file all necessary post-effective amendments to the registration statement under applicable SEC rules and regulations in order to keep the registration statement currently effective.
The Stock Purchase Agreement may be terminated at any time by the mutual written consent of the parties. Unless earlier terminated, the Stock Purchase Agreement will terminate automatically on the 24-month anniversary of the effective date of the registration statement (which term may not be extended by the parties).2012
 
ADA Innovations
 
In December 2010, the Company reached a Services Agreement with ADA Innovations (“ADA”) for final development and production manufacturing of portable versions (the “Projects”) of the Company’s AsepticSure™ disinfection systems (“ADS”).  A contract containing the terms of the agreement and detailed development plan was executed by the parties in January 2011 and amended in January and May, 2012.
In addition, BiOzone Corporation will remain involved as a development support partner and manufacturer of laboratory equipment, and will assist, as requested, in construction of permanent installations for large-scale industrial applications.  Any and all notes, reports, information, inventions, sketches, plans, concepts, data or other works created by ADA on its behalf under the Services Agreement will be the sole and exclusive property of the Company.
 
The term of the Services Agreement continues until the completion of the development and design projects contemplated by the Services Agreement, unless terminated earlier by either party in accordance with specific notices as outlined in the Services Agreement.  Deliverables will include: (1) the pre-production prototype designed and manufactured to our specifications, (2) design and device content compliant with all North America, Europe and United Kingdom regulatory and licensing agency regulations, (3) a soft launch program managed by ADA and the Company, intended to be followed by increased production, and (4) additional outsourced macro-manufacturing capacity as required, supervised by the parties.  The Company will paypaid ADA as services are provided.were provided and were completed by December 31, 2012.  During the three and nine monthsthree-month period ended September 30,March 31, 2012, the Company incurred research and development expenses totaling approximately $49,000 and $157,000 respectively, as compared to approximately $205,000 and $482,000, respectively,$42,000, for the same periods in 2011for services provided under the Services Agreement.  The ADA agreement was completed as of September 30, 2012.Agreement, which expenses have been included in research and development costs.  No expenses under this contract were incurred during the three-month period ended March 31, 2013.
12
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2012 and December 31, 2011

NOTE 98     ACCOUNTS PAYABLE – RELATED PARTIES
 
As of September 30, 2012March 31, 2013 and December 31, 2011,2012, the Company had outstanding $259,609$234,608 and $229,669,$234,572, respectively, owed to certain
consultants for unpaid previous years services.services rendered in prior years. These consultants are stockholders of the Company and therefore have been classified as related parties.

NOTE 10  CUSTOMER DEPOSITS
As of September 30, 2012 and December 31, 2011, the Company had outstanding $50,000 and $40,000, respectively, in customer deposits from orders from customers to purchase our AsepticSure disinfection systems. The Company anticipates deliveries of these units during the fourth quarter of 2012.  These customer deposits have been reflected as current liabilities in the accompanying consolidated balance sheets.
NOTE 119     SUBSEQUENT EVENTS
 
The Company has evaluated events subsequent events perto the requirementsperiod ended March 31, 2013 for potential accounting or disclosure.
In April 2013, the Company and Wood Wyant Canada (“Wood Wyant”), a subsidiary of Topic 855Sanimarc Group, announced that Wood Wyant had become a National Hospital Distributor of AsepticSure in Canada.  Wood Wyant is national in scope and notes that there are no eventsregional in focus, serving Canada from 16 diverse locations across all 10 provinces, providing both sales and service to be reported.the hospital market.  The Company delivered an initial order of 5 systems to Wood Wyant for proceeds totaling $375,000.  The Company has 10 more systems in production for Wood Wyant.
 
 
1312

Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations
 
Introduction
 
Medizone International, Inc. and its subsidiaries (collectively, “Medizone,” the “Company,” “we,” “us,” or “our”) ishas been a development stage company conducting research into the use of ozone in the disinfection of surgical and other medical treatment facilities and in other applications.
Ozone is a gas composed of three oxygen atoms (O3) in an unstable and highly reactive form. Ozone naturally tends to seek its normal state, exhibiting a short half-life as it reverts back to oxygen (O2) fairly rapidly. There are many uses of ozone as a disinfecting agent. Although Ozone does react with organic matter it leaves no residue in water or on the treated product. Ozone also does not form any toxic byproducts and when used in water which means that no change in color or flavor results from ozone treatment, unlike chlorine treatment. Ozone can be generated onsite from ambient air or from oxygen. Each method has its advantages and unique challenges. It has been demonstrated that ozone can be economically produced and is effectively used as an agent in food processing, equipment sanitizing, and in water treatment facilities globally. Ozone technology is replacing conventional sanitation techniques such as chlorine, steam, or hot water.
Development of Our Business
Prior to 2008, our research and development activity had been dedicated to (i) seeking regulatory approval of a precise mixture of ozone and oxygen, and the process of inactivating lipid-enveloped viruses for the intended purpose of decontaminating blood and blood products and assisting in the treatment of certain diseases; (ii) developing or acquiring the related technology and equipment for the medical application of our products, including a drug production and delivery system; and, (iii) applying our novel technology to the problem of nosocomial infections world-wide.
Early in 2008, we began to consider other applications of our core technologies and new technologies with lower development costs with the objective of moving us to revenue production in the shortest period of time. This new direction included re-positioning the Company to pursue an initiative in the field of hospital disinfection. Following laboratory results with Bacillus subtilis, an internationally recognized surrogate for anthrax, that produced 7 log reductions (sterilization), we have expanded our research and business plan to include bio-terrorism countermeasures as well as hospital disinfection and critical infrastructure decontamination.
By way of explanation, “log reduction” is a mathematical term (as is “log increase”) used to show the relative number of live microbes eliminated from a surface by disinfecting or cleaning. For example, a “5-log reduction” means lowering the number of microorganisms by 100,000-fold, that is, if a surface has 100,000 pathogenic microbes on it, a 5-log reduction would reduce the number of microorganisms to one, as indicated in the following table:
·1 log reduction means the number of germs is 10 times smaller
·2 log reduction means the number of germs is 100 times smaller
·3 log reduction means the number of germs is 1000 times smaller
·4 log reduction means the number of germs is 10,000 times smaller
·5 log reduction means the number of germs is 100,000 times smaller
·6 log reduction means the number of germs is 1,000,000 times smaller
·7 log reduction means the number of germs is 10,000,000 times smaller
Corporate Operations
This change in our research and development focus was based, in part, on a review of published data on hospital-derived infections, an area of rapidly growing concern in the medical community. We identified an opportunity to build on our experience with ozone technologies and ozone’s bio-oxidative qualities in pursuing this initiative and shifted our near term efforts towards one of our founding tenets, namely that under the right conditions, ozone can be extremely effective at sterilizing biological fluids (blood, serum, and plasma and plasma fractionates) as well as biologically contaminated equipment and spaces.
14
We expect our unique ozone generating technologies will play a vital role in addressing what public health officials and surgeons world-wide are beginning to recognize as “the silent epidemic” (American Academy of Orthopedic Surgeons, May 2008, copy on file with the Company (“AAOS Study”)), a reference to MRSA (Methicillin-resistant Staphylococcus aureus) infection. This is a strain of Staphylococcus aureus bacteria (“staph”) that is resistant to the broad-spectrum antibiotics commonly used to treat it. MRSA can be fatal. According to the AAOS Study, “the number of hospital admissions for MRSA has exploded in the past decade. By 2005, admissions were triple the number in 2000 and 10-fold higher than in 1995.
In 2005, in the United States, 368,600 hospital admissions for MRSA — including 94,000 invasive infections — resulted in 18,650 deaths. The number of MRSA fatalities in 2005 surpassed the number of fatalities from hurricane Katrina and AIDS combined and is substantially higher than fatalities at the peak of the U.S. polio epidemic.” Indeed, biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control or “CDC” (CDC Report, 17 Oct, 2007, copy on file with the Company), as one of the greatest threats to public health and safety in the industrial world. This concern was reflected in an article published in the journal Science (18 July 2008, Vol. 321, pp 356-361, copy on file with the Company) which estimated that hospital-based infections in 2006 accounted for almost 100,000 deaths in the United States. We expect that current data, if available, would indicate that deaths in the United States from hospital-acquired MRSA infections exceed 100,000 per year.
In response to this situation, we have developed a prototype of a highly portable, low-cost, ozone-based technology (“AsepticSure™”) specifically for the purpose of decontaminating and sterilizing hospital surgical suites, emergency rooms, and intensive care units. Since this technology is not considered a medical treatment or a diagnostic device, its development pathway is not subject to a stringent and expensive regulatory review process. We anticipate that the development pathway will be based on independent peer-reviewed science and engineering excellence. Our team is also developing a variant of AsepticSure™ for governmental use with bio-terrorism countermeasures.
During May 2009, we commenced the first of a series of trials designed to confirm that our AsepticSure™ Hospital Disinfection System can rapidly eliminate hospital-based bacterial pathogens known to be responsible for the growing number of deaths and serious infections currently plaguing the healthcare system worldwide. We engaged an internationally recognized expert in medical microbiology and hospital infections to lead these trials.
We commenced a second series of laboratory trials in early June 2009, after the first series produced results that our researchers deemed to have demonstrated significant bactericidal effects against C. difficile, E. coli, Pseudomonas aeruginosa, MRSA and Vanocomycin-resistant Enterococci (“VRE”), the main causative agents of hospital derived nosocomial infections. This second series of laboratory trials resulted in what are estimated to be levels of bactericidal action necessary to achieve our commercial objectives.
In October 2009, we began a third series of laboratory trials to establish the precise protocols necessary to obtain maximum bactericidal action in combination with minimum turn-around times in keeping with normal hospital flow patterns. This third series of laboratory trials was completed during January 2010 and demonstrated predictably greater than 6 logs (99.9999%) of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for anthrax, Bacillus subtilis. Our research has shown that the technology can now achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means. We expect that this development will significantly expand the utility and acceptance or our AsepticSure™ technology.
In connection with our trials described above, we also designed and produced a development prototype which has demonstrated that it can reach both the charge time and saturation requirements of its design criteria. In January 2010, we started mock-up trials for both public (hospital) and government (bio-terrorism countermeasures) applications of our system. Results obtained during early February 2010 demonstrated that every full-scale test run completed in our hospital room mock-up facility had resulted in the total elimination of all bacteria present in the room. Additional testing was designed to confirm in a more realistic hospital setting these laboratory findings indicating extremely high antibacterial efficacy for our novel technology (6-7.2 log reductions) against the primary causative agents of hospital acquired infections (HAIs), sometimes referred to as “Super Bugs.” We completed multiple runs with very high concentrations of MRSA, VRE and E. coli samples that were distributed throughout the test room. In every instance, the AsepticSure™ system produced greater than 6 log (99.9999%) reductions, which by definition, is sterilization. We have now systematically collected empirically verifiable scientific data on all of the remaining causative agents of HAIs. We have also disinfected Bacillus subtilis, the recognized surrogate for anthrax in full-sized room settings to a sterilization standard of >6 log, which we interpret as a positive indicator that AsepticSure™ could play a vital role in the government arena of bio-terrorism countermeasures.
15
We started hospital beta-testing of a prototype system utilizing the original technology during the summer of 2010, with the initial phases successfully completed during early October 2010. The first round of in-hospital beta-testing for this AsepticSure™ hospital disinfection system was completed on October 9, 2010, at a Hotel Dieu hospital in Kingston, Ontario, Canada. The targeted hospital space was artificially contaminated with high concentrations of MRSA and C. difficile, using both regulatory compliant stainless steel discs and carpet samples typically found in many health care facilities. One hundred percent of the MRSA and C. difficile was eliminated from the discs (7.1 logs for MRSA and 6.2 logs for C difficile). The pathogens were also completely eliminated from all contaminated carpet samples, something we believe to be unachievable with any other technology. Testing further indicated that beyond the test samples artificially introduced, all pre-occurring pathogens present before testing were also eliminated on all surfaces by the AsepticSure™ hospital disinfection system.
In addition to the hospital disinfection system, we employ an ozone-destruct unit which is used following disinfection of the treated infrastructure to reverse the O3 gas in the space, and turn it back into O2 in a short period of time. We have initially targeted the treatment of a typically sized surgical suite including disinfection followed by ozone destruct to habitable standards in ninety minutes or less. This short turn-around period is considered of great importance relative to commercialization of the technology.
In addition, work completed by the Company at Queen’s University demonstrated that the AsepticSure™ system can reliably eliminate in excess of 7 logs (99.99999%) reductions of Listeria monocytogenes and Salmonella typhium with 30-minute exposure to our unique and patented gas mixture, which provides an additional application of the AsepticSure™ technology, beyond that of hospital acquired infections for the food processing industry.
Importantly, the AsepticSure™ system is proving equally effective in disinfecting carpets and drapes as well as hard surfaces to greater than 6 log kill (6-log is generally recognized within the scientific community as the standard for sterilization). We are not aware of any other system in the world capable of making this claim that utilizes green technology and allows content to remain in the room during disinfection.
In November of 2011 Medizone awarded the production manufacturing contract for AsepticSure™ to SMTC Corporation (SMTC), headquartered in Toronto, Canada. SMTC maintains manufacturing facilities in Canada, the United States, Mexico and China. We believe SMTC or a similar manufacturer has the capacity to address all AsepticSure™ manufacturing requirements for the foreseeable future.
During January 2012, technology transfer of the production design was completed from ADA Innovations (“ADA”), our production development partner, to SMTC. An initial order was placed for five production validation units to be built. The production validation units are intended to be used for regulatory compliance and licensing validation, additional testing and early delivery positions.
In February 2012, SMTC reported that certain supply-side and tooling delays set back the anticipated delivery date for the initial units by a number of weeks, although the first unit has been delivered. Electrical testing requirements for the unit have been met. The remaining four validation units were delivered in September 2012 and we will use them to fill early delivery positions.
During 2012, we are leavingemerged from the development stage as we have commenced planned principal operations.  During the three months ended September 30, 2012, we (a) delivered units and finalized sales totaling $150,000; (b) received deposits for units ordered for delivery in the next few months totaling $50,000; and (c) expect an additional $55,000 (as $20,000 has already been collected as a deposit by us as described above in (b)); for purchase of a unitbegan to be delivered to a New Zealand company during the fourth quarter of 2012.
At this time, based on the number of inquiries we are receiving, and the fact that the HAI problem continues to grow worse globally based on frequent media reports, we expect to see significant product demand as we increase production. We currently anticipate we will have delivered or have on order approximately 40 machines by the end of the first quarter of 2013.
While the Company’s intention is to expand distribution in the North American market first, significant seed work has already taken place with potential corporate distribution partners in Europe, parts of Asia and Brazil.  Distribution into those markets should not be anticipated until after distribution into the North American market is more fully developed.
16
International Recognition of AsepticSure™
In May 2011, a prestigious peer review medical journal, The American Journal of Infection Control (“AJIC”), e-published a peer-reviewed article on the science of AsepticSure™ and its unprecedented micro microbialsell our patented ozone disinfection ability. (> 6 log kill for all pathogens tested), titled: “Effectiveness of a novel ozone-based system, for the rapid high-level disinfection of health care spaces and surfaces,” authored by Dick Zoutman, MD, FRCPC, Michael Shannon, M.A., M.Sc., M.D., and Arkady Mandel, M.D., Ph.D., D.Sc., Kingston, and Ottawa, Ontario, Canada. The review was based on the work completed at our laboratories located at Innovation Park, Queen’s University, in Kingston, Ontario, Canada. The print edition of the article appeared in the December 2011 issue of the AJIC.
In July 2011, canadaNOW, a bi-annual national magazine of the Canadian university research parks, featured AsepticSure™ in an article titled, “Taking on the ‘silent epidemic.” Also in July 2011, AsepticSure™ was awarded one of three Awards for Innovation at the First International Conference on Prevention and Infection Control (ICPICP) sponsored by the World Health Organization in Geneva, Switzerland.AsepticSure.
 
Recent Developments
 
In June 2012, we announced that we had achieved 100% kill rates with tuberculosis in three successive trials. This represents another important milestone in our understandingWe took delivery at the end of the antimicrobial limits of our recently launched disinfection technology, AsepticSure™.
According to Dr. Michael E. Shannon, our President, approximately one-third of the world’s population is currently infected with tuberculosis and a new Extreme Drug Resistant Strain of tuberculosis is now sweeping across Asia, central Europe and parts of Africa.  These factors drove the Company to evaluate the efficacy of AsepticSure against this daunting bacteria.  With a small increase in treatment time (beyond our standard 90 minute protocol, start to finish) we demonstrated that AsepticSure consistently produces greater than 6 log reductions of Mycobacterium terrae, a well-established surrogate organism for Mycobacterium tuberculosis.  These findings expand upon our ground-breaking research already published in the field of HAI control, with implications not just of academic or scientific interest but of significant public health importance as well.  There are over 200,000 clinical laboratories in the United States and until now, there has been no cost effective way to address their contamination problems.  We believe, based on our testing, that AsepticSure offers an extremely effective and surprisingly inexpensive disinfection and decontamination solution, not only for laboratory contamination problems, but environmental contamination problems worldwide.
During the second quarter 2012, we also announced the appointment of Queen’s University Professor Dr. Dick Zoutman as our new Chief Medical Officer.  In this new role, as well as continuing to provide direct microbiology support to Dr. Shannon, Dr. Zoutman will also report to both the President and the Chief Executive Officer regarding his responsibilities, which include providing:
·  input into the design, planning, initiation and analysis of all beta test and post market surveillance programs worldwide; and
·  direct liaison with clinical investigators, and maintaining professional awareness of our many scientific accomplishments through the preparation of peer-reviewed articles and the preparation of presentations at medical conferences.
We have also obtained the services of Mr. Glen Balzer to lead our management team in the building of both a distributor network and supply side management and manufacturing oversight team.  Mr. Balzer is a recognized expert in both supply side and distribution side team building.
In September 2012, we entered into a Terms and Conditions of Sales, Goods and Manufacturing Contract with Transformix Engineering.  Transformix is a specialty engineering and manufacturing company located in Kingston, Ontario, Canada. A change in manufacturers was sought by us to address delays in product delivery and quality control issues with a prior manufacturer. The Company believes that Transformix has an appropriately deep level of engineering depth in its workforce to meet the needs of the Company.  DeliveryJanuary 2013 of the first AsepticSure systemssystem constructed by our new contract manufacturer, Transformix Engineering, located in Ontario, Canada (“Transformix”).  Transformix delivered an additional three units from the initial build order during February 2013.  The units passed performance confirmation testing at our Innovation Park laboratories.  The build quality of the system appears to be builtvery good.  We believe we now have a manufacturing source that is capable of meeting our anticipated production requirements.
Subsequent to December 31, 2012, Singapore issued us our Health Care Patent (P-no.: 176977 ‒ Healthcare Facility Disinfecting Process and System with Oxygen/Ozone Mixture).  We consider this significant for our business growth in Asia.  According to published reports, the treatment of non-resident and foreign patients (the “medical tourism market”) in Singapore has been growing rapidly and as reported by Transformix is anticipatedthe Singapore press holdings on-line portal AsiaOne, there were approximately 850,000 foreign patients treated in December.  AssumingSingapore medical facilities during 2012, producing revenues of about $3.5 billion.  We believe Singapore could become a successful delivery oflucrative market for AsepticSure sales as the first order, Transformix expectsmedical system there seeks to ramp up productiondistinguish itself with the safest hospitals possible in order to meet estimated sales orderspromote continued growth in the expanding medical tourism market.
In January 2013, we completed successful safety and preliminary operational trials of the AsepticSure system forat the first quarterBelleville General Hospital site of 2103.
17
Regulatory Affairs
The regulatory armAsepticSure services in Canada, these trials are believed to unequivocally demonstrate the safety and ease of Health Canada has given us an opinion letter stating that ouroperation of the AsepticSure disinfection system will not be regulated in Canada as a disinfectant, as there is no surface residual following room treatment.  In addition, AsepticSure will not be regulated in Canada as a medical device.  As a result of this very favorable ruling, we are now free to market AsepticSure infunctioning health care setting.  During the Canadian market.
New Zealand regulatory authorities have taken a similar position totests, the Canadian authorities, making New Zealand the second country in which we are authorized to sell the AsepticSureturnaround time for disinfection system.
We anticipate that the United States will become the third country approving sale of AsepticSure.  The United States Food and Drug Administration (FDA) has ruled that AsepticSure is a Class 1 medical device.  This was expected by our development and regulatory team.  Interaction with both the FDA and Environmental Protection Agency (EPA) in the United States has progressed nicely and we currently anticipate obtaining approval for sale into the United States market in the fourth quarter of 2012 or the first quarter of 2013.
Canadian Foundation for Global Health – Consolidated Variable Interest Entity
In 2008, we assisted in the formation of CFGH, a not-for-profit foundation based in Ottawa, Canada. We helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with us for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit, and (2) to provide a means for us to use a tiered pricing structure for services and products in emerging economies and extend the reach of our technology to as many in need as possible.
The CFGH may not contract for research or other services on our behalf without our prior approval. In addition, our understanding with the CFGH provides that all intellectual property, including but not limited to, scientific results, patents and trademarks that are derived from work done on our behalf or at our request by CFGH or parties contracted by CFGH with our prior approval will be our sole and exclusive property.
The CFGH is registered as a not-for-profit corporation under Canadian Federal Charter. Dr. Shannon M.A., M.Sc., M.D. is President of CFGH and maintains offices at CFGH. Mr. Brad Goble, President of TDVGlobal, Inc., is also a board member of CFGH and serves as the Secretary-Treasurer for that organization. According to its website, TDVGlobal, Inc. “is a strategic management consulting company” focusing on the public sector. It is based in Ottawa, Ontario, Canada. Other membersreoccupation of the CFGH board are Edwin G. Marshall (our Chief Executive Officer and Chairman), Daniel D. Hoyt (one of our directors), Dr. Jill C. Marshall, NMD, (Mr. Marshall’s wife and a former corporate officer of the Company), and Dr. Ron St. John.hospital rooms was less than 90 minutes.
We follow the accounting standard which requires a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate it. We have determined that CFGH meets the requirements of a VIE, effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial position and operations of CFGH are being consolidated with our financial results and in our consolidated financial statements included within this quarterly report.
Medizone Canada Limited
We own all of the issued and outstanding stock of Medizone Canada, Ltd., a Canadian corporation (“MedCan”). MedCan was a participant in the Canadian Blood Forces Program’s SIV Study, but is not currently engaged in any business activity.
Employees
As of October 2012, Medizone had a total of 15 full-time employees and consultants.
18

Results of Operations
 
Three Months Ended September 30,March 31, 2013 and 2012 and 2011
 
We were incorporated in January 1986.  We are a company engaged in research and production of ozone based fogging mixture as a disinfectant.  Our current work is in the field of hospital disinfection, and other industrial applications requiring disinfectant, rather than human therapies.  During the three months ended Septemberthird quarter of 2012, we began to sell our AsepticSure product.  We are continuing to develop production equipmentexited the development stage as we commenced planned principal operations.  During the quarter ended March 31, 2013, we had revenues of $4,554 with the intentioncost of increasing sales this year.  However, we cannot predict if we will generate sufficient revenues or cash flow to fund continuing or planned operations.  If we fail to obtain additional funding, we will be forced to suspend or permanently cease operations, and may need to seek protection under United States bankruptcy laws.goods sold of $4,000.

For the three months ended September 30, 2012,March 31, 2013, we had a net loss of $1,072,381,$387,298, compared with a net loss for the three months ended September 30, 2011March 31, 2012 of $485,040.$1,412,061.  The reduction in net loss for the quarter ended March 31, 2013 compared to the same quarter of 2012, was due to options granted to members of the Board of Directors for services rendered as well as consultants for performance bonuses during 2012, which options vested immediately and resulted in $1,057,600 of expense. Our primary expense isexpenses are payroll and consulting fees, research and development costs, office expenses AsepticSure production expenses, together withand interest expense and additional expense recorded as a result of options granted to directors, employees and consultants.expense.
 
For the three months ended September 30,March 31, 2013 and 2012, and 2011, we incurred $932,872$285,211 and $283,730,$1,329,766, respectively, in general and administrative expenses. Our primaryThe majority of these expenses areinclude payroll and consulting fees and professional fees and additionalfees.  The decrease during the three months ended March 31, 2013 over the prior year comparable period was primarily the result of the expense recorded as a result ofassociated with options granted to directors, employees and consultants.members of the Board of Directors as well as consultants for performance bonuses as described above. The remaining general and administrative expenses include rent, office expenses and travel expenses.
 
For the three months ended September 30,March 31, 2013 and 2012, and 2011, we incurred $187,126$85,771 and $189,688,$68,249, respectively, in research and development costs as a result of prototype development costs, consulting, and other research activities.expenses.  Research and development expenses include consultant fees, interface development costs, prototypes, and research stage ozone generator and instrument development.development and remained consistent from the prior year period.
 
Principal amounts owed on notes payable totaled $311,477$307,064 and $283,249 at September 30, 2012$298,536 as of March 31, 2013 and December 31, 2011,2012, respectively.  Interest expense on these obligations during the three months ended September 30,March 31, 2013 and 2012 was $6,366 and 2011 was $6,097 and $6,232,$6,185, respectively. The applicable interest rates on this debt ranged from 7.75 percent7.75% to 10 percent per annum.
Nine Months Ended September 30, 2012 and 2011
For the nine months ended September 30, 2012, we had a net loss of $3,041,730, compared with a net loss for the nine months ended September 30, 2011 of $1,526,519. Our primary expense is payroll and consulting fees, research and development costs, office expenses, together with interest expense and additional expense recorded as a result of options granted to directors, employees and consultants.
For the nine months ended September 30, 2012 and 2011, we incurred $2,514,018 and $712,831, respectively, in general and administrative expenses. The primary increase for the nine months ended September 30, 2012 compared to the same period in 2011, was a result of approximately $1,613,000 of options granted and vested to directors, officers and employees in 2012.  Our primary expenses are payroll, consulting fees, and professional fees. The remaining general and administrative expenses include rent, office expenses and travel expenses.
For the nine months ended September 30, 2012 and 2011, we incurred $546,054 and $778,982, respectively, in research and development costs as a result of prototype development costs, consulting, and other research activities. The primary decrease for the nine months ended September 30, 2012 compared to the same period in 2011, was a result of less research and development costs, prototype development costs, consulting and other research activities as the Company released its product during the three months ended September 30, 2012.  Research and development expenses include consultant fees, interface development costs, prototypes, and research stage ozone generator and instrument development.
Principal amounts owed on notes payable totaled $311,477 and $283,249 at September 30, 2012 and December 31, 2011, respectively.  Interest expense on these obligations during the nine months ended September 30, 2012 and 2011 was $18,445 and $18,910, respectively. The applicable interest rates on this debt ranged from 7.75 percent to 10 percent10% per annum.
 
 
1913
 
Liquidity and Capital Resources
 
At September 30, 2012,As of March 31, 2013, our working capital deficiency was $3,157,206$3,283,615, compared to a working capital deficiency of $3,264,298 at$3,307,973 as of December 31, 2011.2012. We have incurred significant losses from inception through March 31, 2013, which have resulted in an accumulated deficit of $30,472,290.  The stockholders’ deficit at September 30, 2012as of March 31, 2013 was $29,783,028,$3,293,760, compared to $26,741,298 at$3,314,099 as of December 31, 2011.2012 due to sale of restricted shares of common stock being greater than the net loss for the three month period ended March 31, 2013.
 
As described above,In 2012, we are no longer a Development Stage Company, asemerged from the Company began selling its AsepticSure product during the three months ended September 30, 2012.development stage.  We will continue to require additional financing to fund operations and to continue to fund the research necessary to undertake our new business plans to further the ongoing testing, as previously described, and then to market a system forour hospital and medical sterilization. As discussed above,disinfection system.  We believe that we will need approximately $2,000,000 over the Company entered intonext 12 months for continuing research expenses, marketing, product manufacturing and related activities, as well as for general corporate purposes.
            During the Common Stock Purchase Agreement (“Stock Purchase Agreement”) with Mammoth Corporation (“Mammoth”), in November 2010, and establishedthree months ended March 31, 2013, we generated cash of $367,000 through the equity line financing facility (or “Equity Line”).sale of 12,233,332 shares of common stock to 12 accredited investors at a price of $0.03 per share.  We do not anticipate needing to draw the full amount of the Equity Line to implement our business plan and to develop and market our disinfection technologies. We expect that additional capital will come primarily from the Equity Line to continue our activities and to sustain operations. Also, we anticipate that we will be able to raise additional funds, as needed, from somecertain of the same accredited investors who have purchased shares during previous years, although we have no agreements at this time with any of these investors, and there is no assurance that these investors will purchase additional shares.

Going Concern

Our unaudited financial statements included in this report have been prepared on the assumption that the Company will continue as a going concern. There is substantial doubt that the Company will be able to continue as a going concern.  Through the date of this report, it has been necessary to rely upon financing from the sale of our equity securities to sustain operations as indicated above. Additional financing will be required if we are to continue as a going concern. If additional financing is not obtained in the near future, we will be required to curtail or discontinue operations, or seek protection under the bankruptcy laws. Even if additional financing becomes available, there can be no assurance that it will be on terms favorable to the Company. In any event, this additional financing will likely result in immediate and possibly substantial dilution to existing shareholders.
 
Forward-Looking Statements and Risks Affecting the Company
 
The statements contained in this report on Form 10-Q that are not purely historical are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements regarddiscuss our expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future. They may be identified by the use of the words or phrases “believes,” “expects,” “anticipates,” “should,” “plans,” “estimates,” and “potential,” among others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue and expense levels in the future and the sufficiency of existing assets to fund future operations and capital spending needs. Actual results could differ materially from the anticipated results or other expectations expressed in such forward-looking statements for the reasons detailed in our Annual Report on Form 10-K for the year ended December 31, 2011.2012.
 
We believe that many of the risks previously discussed in our SEC filings are part of doing business in the industry in which we operate and compete and will likely be present in all periods reported. The fact that certain risks are endemic to the industry does not lessen their significance. The forward-looking statements contained in this report are made as of the date of this report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements. Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:
 
·Rigorous government scrutiny and regulation of our products and planned products;

·Potential effects of adverse publicity regarding ozone and related technologies or industries;

·Failure to sustain or manage growth including the failure to continue to develop new products; and

·The ability to obtain needed financing.
 
 
2014
 
Critical Accounting Policies and Estimates
 
This Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our unaudited consolidated financial statements, which have been prepared in accordance with accounting principlesUS generally accepted in the United States of Americaaccounting principles (“US GAAP”). The preparation of such statements requires our management to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. By their nature, these judgments are subject to an inherent degree of uncertainty. On an on-going basis, we evaluate these estimates, including those related to intangible assets, expenses, and income taxes. We base our estimates on historical experience and other facts and circumstances that are believed to be reasonable, and the results form the basis for making judgments about the carrying value of assets and liabilities. The actual results may differ from these estimates under different assumptions or conditions.
 
We commenced sales and emerged from the development stage in 2012.  We recognize revenue when a contractual arrangement exists, product is shipped, payment from the customer is reasonably assured, and the price is fixed or determinable.  We record customer deposits that have not yet been earned as unearned revenue. Revenue is recognized only when title and risk of loss passes to customers.

Our inventory consists of our AsepticSure product and is valued on a “specific identification basis.”  We purchase our inventory as a finished product from unrelated manufacturing companies. We write off 100% of the cost of inventory that we specifically identify and consider obsolete or excessive to fulfill future sales estimates. We did not deem any inventory obsolete or excessive as of March 31, 2013.

We account for equity securities issued for services rendered at the fair value of the securities on the date of grant.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk
 
We are exposed to changes in prevailing market interest rates affecting the return on its investments but do not consider this interest rate market risk exposure to be material to our financial condition or results of operations. We invest primarily in United States Treasury instruments with short-term (less than one year) maturities. The carrying amount of these investments approximates fair value due to the short-term maturities. Under current policies, we do not use derivative financial instruments, derivative commodity instruments or other financial instruments to manage our exposure to changes in interest rates or commodity prices.None.
 
Item 4.  Controls and Procedures
 
Evaluation of Disclosure Controls and Procedures
 
As of September 30, 2012,March 31, 2013, we updated our evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for purposes of filing reports under the Exchange Act. This controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and our chief financial officer. Our chief executive officer and our chief financial officer concluded that at September 30, 2012,as of March 31, 2013, our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) are effective to provide reasonable assurance that information that we are required to disclose in the reports that we file or submit to the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are designed to provide reasonable assurance that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
 
Changes in Internal Controls
 
We maintain a system of internal control over financial reporting that is designed to provide reasonable assurance that our books and records accurately reflect our transactions and that our established policies and procedures are followed. There were no changes to our internal control over financial reporting during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
 
2115
 
PART II — OTHER INFORMATION
 
Item 1.  Legal Proceedings
 
There were no material developments during the quarter ended September 30, 2012March 31, 2013 relative to the legal matters previously disclosed by the Company.
 
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds
 
During the three-month period ended September 30, 2012,March 31, 2013, we sold 5,233,333an aggregate of 12,233,332 restricted shares of common stock to 1112 accredited investors for cash proceeds totaling $296,500, ranging from $0.05 to $0.09$367,000, or $0.03 per share. The purchasers of the shares were primarily current shareholdersstockholders of, but not otherwise affiliated with the Company. There were no underwriters or public solicitation involved in the offer or sale of these securities. The proceeds wereare being used for general operating expenses and the continuing development of the AsepticSure™ hospital disinfection system. The offer and sale of these securities was made without registration under the Securities Act in reliance upon exemptions from registration, including, without limitation, the exemption provided under Section 4(2) of the Securities Act for private and limited offers and sales of securities made solely to accredited investors.
 
Item 5.  Other Information
None.

Item 6.  Exhibits
 
Exhibit 31.1
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 31.2
Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.1
Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.2
Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**
101.INSXBRL Instance DocumentDocument**
101.SCH**101.SCHXBRL Taxonomy Extension SchemaSchema**
101.CAL**101.CALXBRL Taxonomy Extension Calculation LinkbaseLinkbase**
101.DEF**101.DEFXBRL Taxonomy Extension Definition LinkbaseLinkbase**
101.LAB**101.LABXBRL Taxonomy Extension Label LinkbaseLinkbase**
101.PRE**101.PREXBRL Taxonomy Extension Presentation LinkbaseLinkbase**
 
** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) and otherwise are not subject to liability.

 
2216
 
SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDIZONE INTERNATIONAL, INC.
(Registrant)
October 25, 2012By:/s/ Edwin G. Marshall
Edwin G. Marshall
Chairman and Chief Executive Officer
(Principal Executive Officer)
October 25, 2012By:/s/ Thomas (Tommy) E. Auger
Thomas (Tommy) E. Auger
Chief Financial Officer
(Principal Financial and Principal Accounting Officer)

/s/ Edwin G. Marshall                                
Edwin G. Marshall, Chairman and Chief Executive
Officer (Principal Executive Officer)

/s/ Thomas (Tommy) E. Auger                 
Thomas (Tommy) E. Auger, Chief Financial Officer
(Principal Financial and Accounting Officer)

April 26, 2013
 
2317